Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more ...

The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.

FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...

T'puram: The new Coast Guard jetty at Vizhinjam was inaugurated by director general S Paramesh in the presence of inspector ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

A new coast guard jetty has been inaugurated at Vizhinjam to enhance safe berthing and quick deployment of surface assets.

The absence of Belarusian flag next to Aryna Sabalenka's name at the French Open has drawn attention. Instead, a plain blue ...

Movember ? the world's leading men's health charity ? has released the Real Face of Men's Health Report (the report) detailing new findings on the state of men's health in Canada. The report reveals ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...